Drugs / CBT-008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05261386 | Mar → Sep 2022 | eye adnexa disorder | Cloudbreak Therapeutics, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBT-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05261386 ↗ |
| Route | Topical | “CBT-008 topical ophthalmic solution” NCT05261386 ↗ |